From Wikipedia:
Exubera, inhalable insulin developed by Pfizer, was approved for use in 1-2006. In 4-2006, the UK's NIH advised against the use of inhalable insulin on the grounds that avoiding injections did not justify the higher cost of the new product, estimated at £1100 per year. The NIH recommended in 6-2006 that diabetics should use Exubera only if they could establish 1) a medically proven fear of insulin injections or 2) chronic problems with their insulin injection sites.
Novo Nordisk, filed a lawsuit against Pfizer on 8-2006, claiming patent infringement, seeking both compensatory damages and injunctive relief. Novo sought an injunction preventing the release of Pfizer's 9-2006 launch of Exubera. A federal judge delayed a decision on Novo Nordisk's request for injunctive relief until 12-2006 court hearing. Pfizer's answer contends Novo wants to deny diabetics access to Exubera because it's the only FDA approved inhalable insulin & would hurt Novo Nordisk's business.
2006-11-11
17:27:24
·
14 answers
·
asked by
x
5